← All trials
NCT07289945
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 15, 2024
- Primary completion
- Apr 15, 2025
- Completion date
- Apr 15, 2025
- First posted
- Dec 17, 2025
- Last posted
- Dec 17, 2025
- Enrollment
- 81
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Rouen Normandy UniversityLead sponsor
- Rouen Normandy UniversitySponsor investigator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.